Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

‘Omics’ biomarkers associated with chronic low back pain: protocol of a retrospective longitudinal study (CROSBI ID 236814)

Prilog u časopisu | ostalo

Allegri, Massimo ; De Gregori, Manuela ; Minella, Cristina E ; Klersy, Catherine ; Wang, Wei ; Sim, Moira ; Gieger, Christian ; Manz, Judith ; Pemberton, Iain K ; MacDougall, Jane et al. ‘Omics’ biomarkers associated with chronic low back pain: protocol of a retrospective longitudinal study // BMJ Open, 6 (2016), 10; e012070-1-e012070-8. doi: 10.1136/bmjopen-2016-012070

Podaci o odgovornosti

Allegri, Massimo ; De Gregori, Manuela ; Minella, Cristina E ; Klersy, Catherine ; Wang, Wei ; Sim, Moira ; Gieger, Christian ; Manz, Judith ; Pemberton, Iain K ; MacDougall, Jane ; Williams, Frances MK ; Van Zundert, Jan ; Buyse, Klaas ; Lauc, Gordan ; Gudelj, Ivan ; Primorac, Dragan ; Skelin, Andrea ; Aulchenko, Yurii S ; Lennart, C. Karssen ; Kapural, Leonardo ; Rauck, Richard ; Fanelli, Guido

engleski

‘Omics’ biomarkers associated with chronic low back pain: protocol of a retrospective longitudinal study

Chronic low back pain (CLBP) produces considerable direct costs as well as indirect burdens for society, industry and health systems. CLBP is characterised by heterogeneity, inclusion of several pain syndromes, different underlying molecular pathologies and interaction with psychosocial factors that leads to a range of clinical manifestations. There is still much to understand in the underlying pathological processes and the non-psychosocial factors which account for differences in outcomes. Biomarkers that may be objectively used for diagnosis and personalised, targeted and cost- effective treatment are still lacking. Therefore, any data that may be obtained at the ‘-omics’ level (glycomics, Activomics and genome-wide association studies—GWAS) may be helpful to use as dynamic biomarkers for elucidating CLBP pathogenesis and may ultimately provide prognostic information too. By means of a retrospective, observational, case-cohort, multicentre study, we aim to investigate new promising biomarkers potentially able to solve some of the issues related to CLBP

chronic low back pain (LBP), Omics biomarkers, retrospective study

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

6 (10)

2016.

e012070-1-e012070-8

objavljeno

2044-6055

10.1136/bmjopen-2016-012070

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost